Updated Executive Summary: NAD+ and its precursors supplementation – a state-of-the-art review
Background: There is considerable public and commercial interest in NAD+ and its precursors (such as NR and NMN), which are often marketed as ‘anti-aging’ supplements. In light of this, and in light of the evolving scientific research in this area, this review critically examines the current evidence regarding their efficacy, safety, and clinical potential. This summary summarizes the key findings.
Essentiality and decline with age: NAD+ is an essential coenzyme for hundreds of cellular processes (including energy production and DNA repair). Its levels in the body naturally decline with age, a process associated with aging and many chronic diseases.
Increasing NAD+ levels: Supplements containing precursors such as NR and NMN have been shown to significantly increase NAD+ levels in the body (for example, one formula demonstrated a 74% increase in blood levels within 4 weeks).
Longevity: There is currently no evidence that NAD+ supplementation extends lifespan in humans. In animal models, results are mixed and inconsistent: NR did not extend lifespan in a large NIH study in rodents, and an initial (unpeer-reviewed) NMN study showed lifespan extension only in mice—a finding that requires further validation.
Metabolic health: The benefit appears to depend on the initial metabolic state. In healthy or obese individuals without metabolic disorders, significant improvement is generally not observed. In contrast, in at-risk populations, such as women with prediabetes, NMN has shown improvements in insulin sensitivity. The effect may be limited primarily to individuals with an existing metabolic disorder.
Cognitive function and neurodegenerative diseases: There is a strong biological rationale and encouraging results in laboratory animal studies (reduction of inflammation and improvement of memory). However, clinical studies in humans are limited and have not shown clear cognitive improvement in functional measures, even when an effect on biomarkers or blood NAD+ levels was observed. More encouraging initial results have been reported in Parkinson’s disease (slight improvement in symptoms with NR), and a large study (NO-PARK) is underway.
Cardiovascular health: There is currently no convincing evidence that NR or NMN directly improve cardiovascular health in humans. Few studies have shown at most modest effects on blood pressure, with no reduction in cardiovascular events. The evidence for niacin (vitamin B₃, a classic precursor) is also complex and does not support widespread use for cardiovascular prevention today.
Exercise performance and endurance: Results are mixed And the effect appears minimal, if any. Slight improvements in submaximal endurance have been observed in some studies (mainly with NMN in untrained individuals), but no consistent and significant improvement in maximal fitness measures (VO₂max, power) in most studies.
Cancer – Risks vs. Benefits: The effects are complex and a double-edged sword. On the one hand, early evidence from animal studies suggests a potential for preventing or protecting healthy cells from chemotherapy damage. On the other hand, there are significant concerns, also based on animal studies, that NAD+ supplementation may “fuel” existing tumors, protect them from treatment, or even accelerate the development of metastases. Extreme caution is required in any oncological context.
Safety and Dosages: In the short term and at the doses tested so far (up to about 1–2 grams per day), NR/NMN supplements are considered relatively safe and well tolerated, with minor side effects whose incidence is often similar to placebo. Long-term safety data are lacking. The optimal dose to achieve different effects has not yet been determined, and studies have used a wide range of doses. Formulations to improve absorption (such as sublingual or liposomal) may improve the effectiveness of supplements.
Conclusions and Recommendations: To date, there is no strong scientific evidence that NAD+ precursor supplementation is a “miracle cure,” a sweeping anti-aging intervention, or that it prolongs life in humans. There are encouraging initial findings in specific areas (such as metabolic improvement in at-risk states or early signs of Parkinson’s), but the broad efficacy requires validation in large, long-term clinical trials. Proven lifestyle changes (exercise, proper nutrition, quality sleep) remain the central, safest, and most effective strategy for promoting health and longevity. NAD+ supplementation should be approached with caution, with realistic expectations, and currently primarily as a research or As a potential complementary therapy for specific niches, rather than a substitute for a healthy lifestyle..
1. Introduction: NAD+ as a key intersection in aging and health
The widening gap between life expectancy and health expectancy in the modern era has placed the search for interventions to promote “healthy longevity” at the forefront of biomedical research. However, this field is saturated with marketing promises, and distinguishing between scientifically based hope and unfounded enthusiasm is a constant challenge. One of the main candidates that has received extraordinary research and public attention in this context is nicotinamide adenine dinucleotide (NAD+).
NAD+ is an essential coenzyme that plays critical roles in hundreds of cellular processes, including energy metabolism, DNA damage repair, and gene expression regulation. Its fundamental importance for cellular function is unquestionable. Numerous studies indicate an age-dependent decline in NAD+ levels in various tissues, a phenomenon that has been linked to the characteristics of biological mechanisms of aging and the development of associated chronic diseases. Against this background, there has been great interest in developing strategies to increase NAD+ stores, mainly through the supplementation of precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). These supplements are often marketed with the promise of improving metabolic, cognitive, and physical health, and even extending lifespan.
The central question that this review will address is the extent to which these claims are scientifically substantiated. What are the mechanisms by which changes in NAD+ levels may affect the aging process, and what is the quality of the supporting evidence, both from preclinical studies and from human clinical trials? This review will critically assess the place of NAD+ and its precursors in the longevity medicine discourse, examining the biological basis and the gaps between the promise and the existing scientific evidence.